Schonfeld Strategic Advisors’s Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share IBER.WS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IBER.WS Stock Details IBER.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-54,178	Closed	-$11K	–	3227
2022 Q1	$11K	Hold	54,178	–	–	﹤0.01%	2419
2021 Q4	$29K	Sell	54,178 -13,544	-20%	-$7.68K	﹤0.01%	1969
2021 Q3	$40K	Buy	+67,722	New	+$45.5K	﹤0.01%	2016

Other funds holding IBER.WS

LCM

Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return

Schonfeld Strategic Advisors's IBER.WS Position: Q1 2023 in Review

Schonfeld Strategic Advisors sold out of Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share (IBER.WS) in Q1 2023, closing a stake of 53,578 shares — an estimated $525 sold.

Schonfeld Strategic Advisors first reported a position in IBER.WS in Q2 2022 and held it in 3 quarters. The position peaked at $5K in Q3 2022. 1 fund tracked by Wall St. Rank holds IBER.WS as of Q1 2023.

Schonfeld Strategic Advisors reported no remaining Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position as of Q1 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 53,578 Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share shares in Q1 2023, an estimated $525.
Schonfeld Strategic Advisors first reported a position in Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share in Q2 2022 and held it in 3 quarters.
Schonfeld Strategic Advisors's Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share position peaked at $5K in Q3 2022.
1 fund tracked by Wall St. Rank held Ibere Pharmaceuticals Redeemable Warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share as of Q1 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2023, filed 15 May 2023.